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Abstract  23 
Measuring anti-HPV antibody levels is important for surveillance of the immunological 24 
response to both natural infection and vaccination. Here, an ELISA test for measurement of 25 
HPV-16L1 antibodies was developed and validated in sera and dried blood spots.  26 
An in-house ELISA was developed for measuring anti-HPV-16L1 IgA and IgG levels. The 27 
assay was standardized against WHO international standard serum and validated on serum, 28 
dried blood spots and cervical liquid based cytology samples from women attending 29 
colposcopy clinics in Scotland. Antibody avidity index was also measured in serum samples. 30 
The average HPV 16-L1 specific IgG and IgA levels measured in sera, in women attending a 31 
routine colposcopy service were 7.3 units/ml and 8.1 units/ml respectively. Significant 32 
correlations between serum and dried blood spot eluates for both IgG and IgA were observed 33 
indicating that the latter serve as a credible proxy for antibody levels.  Average IgG Avidity 34 
Index was 35% (95% CI 25%-45%) suggesting previous, historical challenge with natural 35 
infection. This ELISA has potential for use in epidemiological and field studies of antibody 36 
prevalence and if coupled with avidity measurement may be of use in individual case 37 
monitoring of vaccine responses and failures.  38 
Keywords: HPV16, Antibody response, Avidity, Dried Blood spots  39 
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Introduction 40 
Human Papillomavirus (HPV) infections are very common in the general population with an 41 
estimated 10-15% prevalence in women of cervical screening age (Crow, 2012). While most 42 
HPV infections are cleared naturally within 2 years, persistent infection with one of the “high-43 
risk” HPVs (HR-HPV) is associated with development of cervical cancer. Two high-risk types, 44 
16 and 18, are associated with over 70% of cervical cancers (Crow, 2012), which has informed 45 
prophylactic vaccine design and implementation. In addition, HR-HPV infection is strongly 46 
associated with development of vaginal, vulval, penile, anal and oropharyngeal cancers 47 
(Schiffman et al., 2016).   48 
As only a minority of those infected with HPV develop disease the host immune response is 49 
clearly important in the regulation and trajectory of the infection. This is also evidenced by the 50 
fact that immunocompromised individuals are at a greater risk of HPV-associated clinical 51 
morbidity (Reusser et al., 2015). Antibodies are important for protective immunity against HPV 52 
infection and neutralising antibodies against the major capsid protein L1 of the virus are 53 
efficacious against infection with 16/18, which is the rationale behind vaccine design. 54 
Currently three prophylactic vaccines are licensed for use – the bivalent vaccine which confers 55 
protection against types 16 and 18, the quadrivalent vaccine which protects against 16, 18, 6 56 
and 11 and the nonavalent vaccine which protects against HPV 6, 11, 16, 18, 31, 33, 45, 52 and 57 
58. The rate of seroconversion associated with the licensed vaccines is high, with reports of 58 
>99% seroconversion in both immunocompetent males and females (Paavonen et al., 2007; 59 
Van Damme et al., 2015; Villa et al., 2006; Viscidi et al., 2004). Comparatively seroconversion 60 
as a consequence of natural infection is low with rates of around 50-70% in women (Carter et 61 
al., 2000) and 4-36% in men (Edelstein et al., 2011), with the average time to seroconversion 62 
8-9 months after HPV infection (Carter et al., 2000). In addition, concentrations of anti-63 
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HPV16L1 serum antibody associated with natural infection are significantly lower than levels 64 
generated as a consequence of vaccination (Carter et al., 2000).  The lower titres of antibodies 65 
generated as a consequence of natural infection, when compared to those generated by the 66 
vaccine, are due to the non-lytic nature of the virus, the lack of viraemia and the fact that the 67 
epithelia, (the obligate target cells for natural infection) are relative sparse with respect to 68 
immune effector cells. In comparison as the vaccine is delivered by intra-muscular injection(s) 69 
more immediate and comprehensive exposure to immune effector cells generates high titres of 70 
antibodies. 71 
HPV serology is an essential tool which can provide key insight into the natural history of HPV 72 
infection particularly given that molecular detection of HPV using nucleic acid amplification 73 
tests cannot determine previous infection. Furthermore, serological tools provide valuable 74 
information on the longevity and magnitude of antibody responses to vaccination which, 75 
through linkage to clinical outcomes, are essential in informing vaccine regimens and 76 
indications, as well as vaccine failures. Avidity testing can additionally inform the quality of 77 
antibody response.  However, compared to molecular HPV assays which number over 200 78 
(Poljak et al., 2016) there are relatively few HPV serology tests, particularly non-proprietary 79 
ones. Most serology tests are in-house and not standardised against the WHO International 80 
standard sera (Bissett et al., 2012). Another challenge in conducting sero-epidemiology is the 81 
practicality of obtaining and processing venous blood, particularly in the context of large 82 
population based studies. Dried blood spots offer clear operational advantages in terms of 83 
capture, storage and transport, although to our knowledge only two studies have determined 84 
the feasibility of this approach (Louie et al., 2018; Waterboer et al., 2012).  85 
In light of this, the objectives of the present work were to develop an in house ELISA for the 86 
measurement of anti-HPV 16-L1 antibodies and perform avidity measurement. The ELISA 87 
was calibrated to the WHO international serum standard. Application of the assay in a 88 
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prospective colposcopy population allowed antibody titres in serum and dried blood spots to 89 
be compared.  90 
 91 
Materials and Methods 92 
Governance 93 
Ethical approval was obtained for prospective sample collection from Scotland A Research 94 
Ethics Committee (REF 12/SS/0034).  95 
Colposcopy cohort from prospective collection- venous blood and cervical liquid based 96 
cytology (LBC) samples 97 
The British Association for Cytopathology (BAC) reporting guidelines and the cervical 98 
intraepithelial neoplasia (CIN) nomenclature were used to classify cytological findings and 99 
histological outcomes, respectively (Smith and Patnick, 2013). Management of women with 100 
abnormal cytological results was performed according to guidelines and algorithms associated 101 
with the United Kingdom National Health Service Cervical Screening Programme (NHS CSP), 102 
modified for use in the Scottish context (Hirschowitz, 2012; Smith and Patnick, 2013). 103 
Unvaccinated women attending the NHS Lothian Colposcopy clinics after a diagnosis of 104 
moderate or severe cytological abnormality were recruited to the study. The median age was 105 
29 years (21-59 years). Informed consent was obtained from participants for provision of a 106 
blood and LBC sample at the time of colposcopy visit. Biopsies were performed as routinely 107 
indicated, and study results did not influence clinical management. A total of 96 serum samples 108 
were collected of which 95 had matching LBC samples (Figure 1).  109 
Clinical sample collection and processing  110 
Blood 111 
Venous blood was collected and serum and blood spots were prepared. Blood spots were 112 
prepared using two 75 µl spots on Guthrie spot filter papers. The spots were air dried and stored 113 
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at 4ºC for 24hrs following which blood was eluted using 800µl PBS/0.05% Tween. Serum was 114 
separated from the remaining blood by centrifugation at 12000g.  115 
Cervical LBC samples 116 
Cervical liquid based cytology samples derived  from the clinic were collected into 20ml of 117 
Preservcyt. Samples were passed through a blunt needle three times to make a uniform cell 118 
suspension, aliquotted and stored at -20ºC.  119 
HPV testing of LBC samples 120 
Genotyping was performed on the LBC samples using the Optiplex HPV Genotyping Kit 121 
(Diamex GmbH) (Kavanagh et al., 2013) which genotypes 18 high-risk or putatively high-risk 122 
types and 6 low-risk types according to the current IARC classification.   123 
ELISAs for anti-HPV16 IgG and IgA antibodies in sera and blood spots  124 
Human International Standard (IS) serum against HPV16 (WHO International Standard 05-125 
134 HPV 16 antibodies NIBSC code: 05/134) was obtained from The National Institute for 126 
Biological Standards and Control (NIBSC, South Mimms, UK) and reconstituted to a 127 
concentration of 10 International Units (IU) of HPV16 L1 specific antibody/ml according to 128 
instructions (Ferguson et al., 2011). To detect high affinity antibodies which reflect a strong 129 
immune response, 2-fold dilution(s) from 1 in 1000 to 1 in 64,000 of the IS serum were made 130 
and used to create a standard curve (Fig 2a). The standard curves were tested 8 times and in 131 
duplicate on each subsequent plate. All serum samples were tested in duplicate at 1 in 2000 132 
dilutions.  133 
For consistency between the amount of total protein in serum and blood spot eluate dilutions, 134 
we calculated the lowest amount of protein in serum as 3 µg/ml at a 1 in 2000 dilution. 135 
Therefore, blood spot samples were tested at a protein concentration of 3 µg/well. It should be 136 
noted that protein in the blood spot eluates also contained protein from all blood cells as well 137 
as plasma. 138 
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Successful IgG and IgA binding with the IS sera for HPV16L1 protein (AbCam, Cambridge, 139 
UK) was obtained when the antigen was used at 50ng/well (500ng/ml) (data not shown,) so 140 
this concentration was used subsequently for all samples. HPV16L1 protein was diluted in 100 141 
ul PBS and coated onto ELISA grade 96 well NUNC MaxiSorp®plates (eBiosciences, Hatfield 142 
UK) by overnight incubation at 4ºC. The wells of the plate were decanted and blotted on tissue 143 
paper, washed x5 with PBS containing 0.1% Tween20 (wash buffer). ELISA buffer (100 µl 144 
PBS containing 1% BSA) was added to each well to block non-specific binding. IS serum 145 
against HPV16L1 protein was pre-absorbed against BSA by diluting to 1 in 200 with ELISA 146 
buffer, incubating overnight at 4 ºC followed by centrifugation at 20,000g for 15 min in a 147 
benchtop microfuge to remove any complexes. The IS serum was then diluted in ELISA buffer, 148 
added to wells and incubated for 1h at room temperature. Plates were washed as above and 100 149 
µl biotinylated-anti-human IgG (1 in 100,000 dilution), or biotinylated-anti-human IgA (1 in 150 
10,000 dilution) both from  Vector Laboratories Ltd (Peterborough, UK), were added to the 151 
wells and incubated for 1h at room temperature. Plates were again washed as above. A 100 µl 152 
volume of streptavidin-horseradish peroxidase complexes (Vector Laboratories Ltd 153 
(Peterborough, UK)) was added to each well and incubated for 1h at room temperature before 154 
plates were again washed as above.  Subsequently, a100 µl volume of TMB (SIGMA (Poole, 155 
UK) reagent was then added to each well and plates incubated at 37ºC for 30 minutes before 156 
the colour reaction was stopped with 1N sulphuric acid. An automated dual filter plate reader 157 
was used to measure absorbance at 450nm/630nm.  158 
Antibody avidity measurement  159 
To determine the avidity index of IgG, we utilised the guanidine hydrochloride method (Inouye 160 
et al., 1984) that has been used previously in studies of anti-HIV (Chawla et al., 2007) and anti-161 
HPV IgG antibodies (Dauner et al., 2012) in human serum. Initial experiments established that 162 
2M guanidine hydrochloride (GuHCL) treatment gave optimal results in the ELISA.  ELISA 163 
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was performed as described above except GuHCL treatment was performed for 15 minutes 164 
before addition of biotinylated anti-human IgG.  Avidity index was measured as the percentage 165 
of IgG (IU/ml) with GuHCL treatment divided by IgG (IU/ml) without treatment. GuHCL has 166 
been reported as a chemical that disrupts the strength of binding between antibody and antigen 167 
and in particular does this without disrupting the VLP structure of HPV 16-L1. Thus GuHCL 168 
was used for the present study 169 
Statistics 170 
Analysis was performed using Graphpad Prism™. Data were tested to determine whether 171 
there was correlation between IgG and IgA in the same samples and between different types 172 
of samples. A p-value < 0.05 was considered to be statistically significant. 173 
Results 174 
Clinical and viral annotation of samples  175 
Of the 96 women in the study cohort with moderate or severe cytological abnormalities, 5 176 
(5.2%) had a biopsy which was reported as normal, 1 woman (1.05%) had CIN1, 40 (41.67%) 177 
had CIN2, 43 (45.2%) had CIN3, 2 (2.1%) had high grade cervical glandular intraepithelial 178 
neoplasia (CGIN) , 1 (1.05%) had small cell cervical carcinoma (SCCC) and 4 were missing 179 
or not definitive (Figure 1).  180 
HPV genotyping was performed on LBC samples from 95 women (one women had no 181 
associated LBC sample collected).  A total of 92 (95.7%) women tested positive for any HPV, 182 
52 had mono-infections and the remainder of HPV positive women had >=2 infections. 183 
HPV16/18 were the most common types (48/91, 52%). In total 72 (75.7%) women were 184 
currently infected with HPV 16 or a related virus in the alpha species group 9 and 20 women 185 
were infected with other HR-HPV types (Figure 1). 186 
Level of anti-HPV16-L1 antibodies in sera 187 
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Anti-HPV16-L1 antibody levels as measure by ELISA in sera from the 96 women were 188 
measured against standard curves of the IS serum (Figure 2a&b). The average HPV 16-L1 189 
specific IgG and IgA levels in the colposcopy population was 7.3 units/ml and 8.14 units/ml 190 
respectively. There was significant correlation between the levels of IgG and IgA anti-HPV16-191 
L1 antibodies in the sera (two-tailed Spearman r=0.5094, p=<0.0001) (Figure 2c) of the 192 
women. There was no significant difference between anti-HPV16-L1 IgG or IgA levels 193 
according to underlying histology (Kruskal Wallis test; no disease IgG versus CIN2+ IgG, 194 
p=0.7531; no disease IgA versus CIN2+ IgA p=0.9905). 195 
Level of anti-HPV16-L1 antibodies in blood spot eluates  196 
All blood spot eluates were tested for total protein concentration and the mean + standard error 197 
of mean (s.e.m) concentration was 1652+41.78 µg/ml. Data for blood spots are given in units 198 
of anti-HPV16-L1 specific antibody (IU)/100 mg protein (Figure 3a) calculated against 199 
standard curves of the IS serum. 200 
Average IgG level in blood spots in the colposcopy population was 3.94 units/ml and the 201 
average IgA level was 12.71 units/ml. There was a significant correlation (two-tailed 202 
Spearman r=0.4900, p=<0.0001) between IgG and IgA antiHPV16L1 antibodies in the blood 203 
spot eluates (Figure 3b). There were also significant correlations between serum and dried 204 
blood spot eluates for the levels of IgG, two-tailed Spearman r=0.2815, p=0.0063 (Figure 3c) 205 
and IgA, two-tailed Spearman r=0.5485, p=<0.0001 (Figure 3d). 206 
Anti-HPV16-L1 antibody levels according to HPV infection  207 
To determine whether serum antibody levels reflected current infection, all serum samples from 208 
women with HPV infection were stratified according to a) having a HPV16 or a 209 
phylogenetically related type which resided in the alpha species group 9 or b) having an other 210 
HPV type, outside the alpha 9 group. Figure 4 shows that, although there was a range in levels 211 
of anti-HPV16L1 antibody, sera from women currently infected with at least one alpha 9 type 212 
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(the majority of whom were HPV 16 positive (n=48/72 alpha 9positive women), showed 213 
significantly higher values of both IgG (Figure 4a) and IgA (Figure 4b) anti-HPV16L1 214 
antibodies compared to those infected with other HPV types. 215 
Avidity index measurement in serum  216 
Antibody avidity (AI) in sera from 34 women who had IgG values for HPV16 of 75% or above 217 
(relative to the International Standard serum) (Figure 5) was assessed. The average avidity 218 
index in the sample set was 34.86 (95% CI- 24.84- 44.88) and of the 34 sera, 33 showed a 219 
significant decrease in antibody levels following GuHCL treatment; the mean + s.e.m % 220 
decrease was 65.14 + 4.929%. 221 
 222 
Discussion 223 
Efforts at detection of HPV antibodies as a tool to monitor and assess vaccine efficacy have 224 
increased significantly in recent years. Several assays, designed to measure HPV antibody 225 
responses in serum are available such as GST- L1 multiplex test (Waterboer et al., 2005), cLIA 226 
(Wentzensen et al., 2011) and in house ELISAs (Mesher et al., 2016). However, there is a lack 227 
of harmonization and standardization of these tests which makes it challenging to compare data 228 
from different studies.  229 
In the present study a reproducible in-house ELISA was developed using widely available 230 
reagents which can robustly detect HPV 16 IgG and IgA in serum and blood spots. The assay 231 
has been calibrated to the international HPV16 serum standard developed by WHO (Pagliusi 232 
et al., 2006). The ability to use dried blood spots has implications for both low resource and 233 
primary care settings as they only require taking a droplet of blood and can be transported to 234 
the lab at ambient temperatures. A correlation between the levels of IgG and IgA was found in 235 
serum, blood spot and LBC samples. A strong correlation between anti-HPV16L1 IgG and IgA 236 
in serum and blood spots was also observed. The present study thus independently validates 237 
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the studies/observations of Waterboer et al (2012), and more recently Louie et al (2018) and 238 
demonstrates the feasibility of using dried blood spots for surveillance purposes. In addition, 239 
the  present work we reference to an international standard (which Waterboer et al did not 240 
incorporate) showed that the ELISA can measure both IgA and IgG effectively. 241 
Another objective of this study was to use the ELISA to investigate the avidity of IgG 242 
antibodies which may provide insight into vaccine efficacy during the longitudinal monitoring 243 
of vaccinated cohorts. 244 
Avidity is the measurement of the strength of interaction between the specific antibody and the 245 
antigen it recognises. During the course of an immune response, antibodies of increasing 246 
avidity for antigen are produced and selected by somatic mutation of the immunoglobulin genes 247 
in antibody producing B lymphocytes.  Generally, avidity of IgG antibodies increases over the 248 
4-6 months following a cleared infection and declines thereafter. Thus a high avidity 249 
measurement indicates a recent or persistent infection. Natural infection with HPV has been 250 
associated with low avidity antibodies as demonstrated recently by Louie et al 2018. 251 
Furthermore, the avidity index (AI) observed in the present study is similar to that observed in 252 
the study of Scherpenisse et al (2013) who reported around 35% AI associated with natural 253 
infection and that the AI of vaccine induced antibodies was around 3 times higher.  AI is 254 
therefore, to an extent a proxy of immunisation-induced antibodies and notably reports that AI 255 
were similar between a 2-dose and 3-dose regimen supported the rationale for 2-dose regimens 256 
(Sankaranarayanan et al., 2016). 257 
 258 
In conclusion, in this study, a standardised ELISA test developed for anti-HPV16L1 antibodies 259 
was validated against the WHO international positive serum standard for HPV16. This assay 260 
was amenable to both venous blood and dried blood spots. While the sample size used for this 261 
study is small, this technique has promise for widespread use in epidemiological and field 262 
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studies of antibody prevalence and coupled with the avidity measurement may be of use in 263 
individual cases for monitoring vaccine responses such as failures. The existence of serological 264 
assays which are calibrated to the same standards will also facilitate cross-study comparison in 265 
the future. 266 
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 393 
Figure legends  394 
 395 
Figure 1. Underlying pathology of the cervical sample set. Details of samples used within 396 
the study. CIN- Cervical Intraepithelial Neoplasia, CGIN- Cervical Glandular Intraepithelial 397 
15 
 
Neoplasia, SCCC – Small Cell Cervical Cancer, HR-HPV – high –risk Human Papilloma 398 
virus.  399 
Figure 2. Measurement of Anti HPV 16 L1 antibodies in sera by ELISA 400 
(A) Linear regression of ELISA standard curves. Mean (solid lines) and 95% confidence 401 
intervals (dashed lines); red lines = IgG; black lines = IgA. Plates coated with 50ng/well 402 
HPV16L1, n=8; r2 for IgG=0.8872; r2 for IgA = 0.9371. OD= optical density. (B) Levels of 403 
IgG and IgA in serum samples calculated against the IS serum standard. Bars show mean + 404 
95% confidence interval, n=94. (C) Correlation between levels of anti-HPV16 L1 IgG and 405 
IgA antibody in sera; n=94; two-tailed Spearman r=0.5248, p=<0.0001. 406 
 407 
Figure 3. Measurement of Anti HPV16 L1 antibodies in eluates from dried blood spots. 408 
(A) IgG and IgA antibody, bars show mean + 95% confidence interval, n=94. (B) Correlation 409 
between levels of anti-HPV16 L1 IgG and IgA antibody in blood spots; n=94; two-tailed 410 
Spearman r=0.4900, p=<0.0001 (C) Correlation between levels of anti-HPV16 L1 IgG 411 
antibody in serum and blood spots; n=95; two-tailed Spearman r=0.2815, p=0.0063. (D) 412 
Correlation between levels of anti-HPV16 L1 IgA antibody in serum and blood spots; n=95; 413 
two-tailed Spearman r=0.5485, p=<0.0001. 414 
Figure 4. Measurement of Anti HPV16 L1 antibodies in sera from women with and 415 
without infection with HPV 16 (or related types) (A) IgG and (B) IgA levels in serum from 416 
women with HPV 16 or a virus that resides in the alpha 9 species group, where HPV 16 is 417 
located (n=72). This is compared to sera from women with unrelated virus types (n=20). Bars 418 
show 95% confidence interval(s), Mann Whitney Test 419 
Figure 5. Measurement of IgG avidityin sera  following treatment with guanidine 420 
hydrochloride (GuHCl). HPV16L1 binding antibodies in 34 sera with IgG levels >75% of 421 
the IS serum were compared before and after GuHCl treatment. (A) 33/34 sera showed a 422 
16 
 
reduction in avidity after treatment; p<0.001, Wilcoxon signed rank test. (B) Avidity index of 423 
antibodies in sera; bars show mean + 95% confidence interval. 424 
 425 
